English

SERES THERAPEUTICS, INC.

EDGAR

MCRB Current report (8-K) · filed 2026-10-26

Annual consolidated revenue for 2025: about USD 789K, using the latest reported figures. The previous period, 2024, was about USD 0.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

736 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 736000 USD Source

Operating margin

-2,890.35%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -21273000 USD Source
Revenue: 736000 USD Source

Operating cash flow

-22.4 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -38754000 USD Source
Operating Cash Flow: -16360000 USD Source

Free cash flow

-22.4 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -38754000 USD Source
Operating Cash Flow: -16360000 USD Source
Capital Expenditure: 0 USD Source
Capital Expenditure: 0 USD Source

Cash and cash equivalents: 15.6 million USD 2026-06-30 Source
Exact value

15594000 USD
Long-term debt including current maturities: 110 million USD 2024-06-30 Source
Exact value

110000000 USD
Shares outstanding: 9.83 million shares 2026-06-30 Source
Exact value

9827569 shares

Reported share-count change

12.26% · 1.07 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

8754482 shares · 2025-06-30· Source
9827569 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

1.88 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 351000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 789000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 351000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 358000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 736000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-22.5 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: 8204000 USD · 2025-07-01 – 2025-09-30 Source
Net income: 5696000 USD · 2025-01-01 – 2025-12-31 Source
Net income: 21031000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -19913000 USD · 2026-01-01 – 2026-03-31 Source
Net income: 4581000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-51.3 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: 15827000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 13621000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: 1117000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: 15827000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -16360000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -38754000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -16360000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

37 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 223000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 215000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 252000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 223000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-51.3 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: 15827000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 13621000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: 1117000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: 15827000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -16360000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -38754000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -16360000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 223000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 215000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 252000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 223000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-26.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 5 of 11 periods available· newest 2023-12-31
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+USD 789,000

Prior period

USD 0

2024-01-01 – 2024-12-31
Current period

USD 789,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

789000 − 0 = 789000 USD

0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
789000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · SERES THERAPEUTICS, INC. · 2025-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Year-over-year change in Revenue: 789000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 789000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2150678 Filing: 000119312526103276 Input fundies:Revenue: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2152276 Filing: 000119312526103276
The citation records this snapshot. The page link may show a newer release later.
Net income
+4,088.2%

Prior period

USD 136,000

2024-01-01 – 2024-12-31
Current period

USD 5.7 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

5696000 − 136000 = 5560000 USD

136000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
5696000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · SERES THERAPEUTICS, INC. · 2025-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Year-over-year change in Net income: 5560000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 5696000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2607698 Filing: 000119312526103276 Input fundies:NetIncome: 136000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2609331 Filing: 000119312526103276
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 149.73 million

Prior period

−USD 148.61 million

2024-01-01 – 2024-12-31
Current period

USD 1.12 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

1117000 − -148609000 = 149726000 USD

-148609000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
1117000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · SERES THERAPEUTICS, INC. · 2025-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Year-over-year change in Operating cash flow: 149726000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 1117000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2744563 Filing: 000119312526103276 Input fundies:OperatingCashFlow: -148609000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2746434 Filing: 000119312526103276
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-33.7%

Prior period

USD 380,000

2024-01-01 – 2024-12-31
Current period

USD 252,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

252000 − 380000 = -128000 USD

380000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
252000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · SERES THERAPEUTICS, INC. · 2025-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Year-over-year change in Capital expenditure: -128000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 252000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2754223 Filing: 000119312526103276 Input fundies:CapitalExpenditure: 380000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2755997 Filing: 000119312526103276
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 789,000 100% of revenue
Operating costs Derived USD 94.76 million 12,010% of revenue
Operating income −USD 93.97 million −11,910% of revenue
Tax, interest and other Derived −USD 99.67 million −12,632% of revenue
Net income USD 5.7 million 722% of revenue

Cash

Operating cash flow USD 1.12 million 142% of revenue
Capital expenditure USD 252,000 32% of revenue
Free cash flow Derived USD 865,000 110% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 527% of revenue.
2017 Operating loss: operating costs were 385% of revenue.
2018 Operating loss: operating costs were 455% of revenue.
2019 Operating loss: operating costs were 308% of revenue.
2020 Operating loss: operating costs were 365% of revenue.
2021 Operating loss: operating costs were 145% of revenue.
2022 Operating loss: operating costs were 2,624% of revenue.
2023 Not shown: operating income or net income is not reported.
2024 Not shown: operating income or net income is not reported.
2025 Operating loss: operating costs were 12,010% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	21766000	114605000 Derived	-92839000	-1260000 Derived	-91579000	22429000 Derived	Source 2016-01-01 – 2016-12-31: 21766000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -92839000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -91579000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: 43921000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 21492000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	32100000	123495000 Derived	-91395000	-2015000 Derived	-89380000	-80199000 Derived	Source 2017-01-01 – 2017-12-31: 32100000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -91395000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -89380000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -75523000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 4676000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	28267000	128551000 Derived	-100284000	-1342000 Derived	-98942000	-64791000 Derived	Source 2018-01-01 – 2018-12-31: 28267000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -100284000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -98942000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -62854000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 1937000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	34505000	106381000 Derived	-71876000	-1597000 Derived	-70279000	-77522000 Derived	Source 2019-01-01 – 2019-12-31: 34505000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -71876000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -70279000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -76520000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 1002000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	33215000	121345000 Derived	-88130000	997000 Derived	-89127000	-94201000 Derived	Source 2020-01-01 – 2020-12-31: 33215000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -88130000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -89127000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -93610000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 591000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	144927000	209420000 Derived	-64493000	1085000 Derived	-65578000	-2878000 Derived	Source 2021-01-01 – 2021-12-31: 144927000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -64493000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -65578000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 6688000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 9566000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	7128000	187042000 Derived	-179914000	70243000 Derived	-250157000	-238637000 Derived	Source 2022-01-01 – 2022-12-31: 7128000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -179914000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -250157000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -228816000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 9821000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	0	195097000 Derived	-195097000	-81373000 Derived	-113724000	-125329000 Derived	Source 2023-01-01 – 2023-12-31: 0 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -195097000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -113724000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -117354000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 7975000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	0	121315000 Derived	-121315000	-121451000 Derived	136000	-148989000 Derived	Source 2024-01-01 – 2024-12-31: 0 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -121315000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: 136000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -148609000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 380000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	789000	94760000 Derived	-93971000	-99667000 Derived	5696000	865000 Derived	Source 2025-01-01 – 2025-12-31: 789000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -93971000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: 5696000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: 1117000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 252000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 789K 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	21766000	Revenue: 21766000 Open source
20172017-12-31	Revenue	32100000	Revenue: 32100000 Open source
20182018-12-31	Revenue	28267000	Revenue: 28267000 Open source
20192019-12-31	Revenue	34505000	Revenue: 34505000 Open source
20202020-12-31	Revenue	33215000	Revenue: 33215000 Open source
20212021-12-31	Revenue	144927000	Revenue: 144927000 Open source
20222022-12-31	Revenue	7128000	Revenue: 7128000 Open source
20232023-12-31	Revenue	0	Revenue: 0 Open source
20242024-12-31	Revenue	0	Revenue: 0 Open source
20252025-12-31	Revenue	789000	Revenue: 789000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 21766000 Open source Revenue: 0 Open source
20172017-12-31	Year over year	47.5%	Revenue: 32100000 Open source Revenue: 21766000 Open source
20182018-12-31	Year over year	-11.9%	Revenue: 28267000 Open source Revenue: 32100000 Open source
20192019-12-31	Year over year	22.1%	Revenue: 34505000 Open source Revenue: 28267000 Open source
20202020-12-31	Year over year	-3.7%	Revenue: 33215000 Open source Revenue: 34505000 Open source
20212021-12-31	Year over year	336.3%	Revenue: 144927000 Open source Revenue: 33215000 Open source
20222022-12-31	Year over year	-95.1%	Revenue: 7128000 Open source Revenue: 144927000 Open source
20232023-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 7128000 Open source
20242024-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20252025-12-31	Year over year	No prior comparable period	Revenue: 789000 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -11,910.1% 2025

Net margin 721.9% 2025

Free cash flow margin 109.6% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-426.5%	Operating Income: -92839000 Open source Revenue: 21766000 Open source
20172017-12-31	Operating margin	-284.7%	Operating Income: -91395000 Open source Revenue: 32100000 Open source
20182018-12-31	Operating margin	-354.8%	Operating Income: -100284000 Open source Revenue: 28267000 Open source
20192019-12-31	Operating margin	-208.3%	Operating Income: -71876000 Open source Revenue: 34505000 Open source
20202020-12-31	Operating margin	-265.3%	Operating Income: -88130000 Open source Revenue: 33215000 Open source
20212021-12-31	Operating margin	-44.5%	Operating Income: -64493000 Open source Revenue: 144927000 Open source
20222022-12-31	Operating margin	-2,524%	Operating Income: -179914000 Open source Revenue: 7128000 Open source
20232023-12-31	Operating margin	Not reported	Operating Income: -195097000 Open source Revenue: 0 Open source
20242024-12-31	Operating margin	Not reported	Operating Income: -121315000 Open source Revenue: 0 Open source
20252025-12-31	Operating margin	-11,910.1%	Operating Income: -93971000 Open source Revenue: 789000 Open source
20162016-12-31	Net margin	-420.7%	Net Income: -91579000 Open source Revenue: 21766000 Open source
20172017-12-31	Net margin	-278.4%	Net Income: -89380000 Open source Revenue: 32100000 Open source
20182018-12-31	Net margin	-350%	Net Income: -98942000 Open source Revenue: 28267000 Open source
20192019-12-31	Net margin	-203.7%	Net Income: -70279000 Open source Revenue: 34505000 Open source
20202020-12-31	Net margin	-268.3%	Net Income: -89127000 Open source Revenue: 33215000 Open source
20212021-12-31	Net margin	-45.2%	Net Income: -65578000 Open source Revenue: 144927000 Open source
20222022-12-31	Net margin	-3,509.5%	Net Income: -250157000 Open source Revenue: 7128000 Open source
20232023-12-31	Net margin	Not reported	Net Income: -113724000 Open source Revenue: 0 Open source
20242024-12-31	Net margin	Not reported	Net Income: 136000 Open source Revenue: 0 Open source
20252025-12-31	Net margin	721.9%	Net Income: 5696000 Open source Revenue: 789000 Open source
20162016-12-31	Free cash flow margin	103%	Revenue: 21766000 Open source Operating Cash Flow: 43921000 Open source Capital Expenditure: 21492000 Open source
20172017-12-31	Free cash flow margin	-249.8%	Revenue: 32100000 Open source Operating Cash Flow: -75523000 Open source Capital Expenditure: 4676000 Open source
20182018-12-31	Free cash flow margin	-229.2%	Revenue: 28267000 Open source Operating Cash Flow: -62854000 Open source Capital Expenditure: 1937000 Open source
20192019-12-31	Free cash flow margin	-224.7%	Revenue: 34505000 Open source Operating Cash Flow: -76520000 Open source Capital Expenditure: 1002000 Open source
20202020-12-31	Free cash flow margin	-283.6%	Revenue: 33215000 Open source Operating Cash Flow: -93610000 Open source Capital Expenditure: 591000 Open source
20212021-12-31	Free cash flow margin	-2%	Revenue: 144927000 Open source Operating Cash Flow: 6688000 Open source Capital Expenditure: 9566000 Open source
20222022-12-31	Free cash flow margin	-3,347.9%	Revenue: 7128000 Open source Operating Cash Flow: -228816000 Open source Capital Expenditure: 9821000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -117354000 Open source Capital Expenditure: 7975000 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -148609000 Open source Capital Expenditure: 380000 Open source
20252025-12-31	Free cash flow margin	109.6%	Revenue: 789000 Open source Operating Cash Flow: 1117000 Open source Capital Expenditure: 252000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 1.1M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	43921000	Operating Cash Flow: 43921000 Open source
20172017-12-31	Operating cash flow	-75523000	Operating Cash Flow: -75523000 Open source
20182018-12-31	Operating cash flow	-62854000	Operating Cash Flow: -62854000 Open source
20192019-12-31	Operating cash flow	-76520000	Operating Cash Flow: -76520000 Open source
20202020-12-31	Operating cash flow	-93610000	Operating Cash Flow: -93610000 Open source
20212021-12-31	Operating cash flow	6688000	Operating Cash Flow: 6688000 Open source
20222022-12-31	Operating cash flow	-228816000	Operating Cash Flow: -228816000 Open source
20232023-12-31	Operating cash flow	-117354000	Operating Cash Flow: -117354000 Open source
20242024-12-31	Operating cash flow	-148609000	Operating Cash Flow: -148609000 Open source
20252025-12-31	Operating cash flow	1117000	Operating Cash Flow: 1117000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 865K 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	22429000	Operating Cash Flow: 43921000 Open source Capital Expenditure: 21492000 Open source
20172017-12-31	Free cash flow	-80199000	Operating Cash Flow: -75523000 Open source Capital Expenditure: 4676000 Open source
20182018-12-31	Free cash flow	-64791000	Operating Cash Flow: -62854000 Open source Capital Expenditure: 1937000 Open source
20192019-12-31	Free cash flow	-77522000	Operating Cash Flow: -76520000 Open source Capital Expenditure: 1002000 Open source
20202020-12-31	Free cash flow	-94201000	Operating Cash Flow: -93610000 Open source Capital Expenditure: 591000 Open source
20212021-12-31	Free cash flow	-2878000	Operating Cash Flow: 6688000 Open source Capital Expenditure: 9566000 Open source
20222022-12-31	Free cash flow	-238637000	Operating Cash Flow: -228816000 Open source Capital Expenditure: 9821000 Open source
20232023-12-31	Free cash flow	-125329000	Operating Cash Flow: -117354000 Open source Capital Expenditure: 7975000 Open source
20242024-12-31	Free cash flow	-148989000	Operating Cash Flow: -148609000 Open source Capital Expenditure: 380000 Open source
20252025-12-31	Free cash flow	865000	Operating Cash Flow: 1117000 Open source Capital Expenditure: 252000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

68% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	51.4%	Total Liabilities: 140015000 Open source Total Assets: 272646000 Open source
20172017-12-31	Liabilities / assets	68%	Total Liabilities: 128823000 Open source Total Assets: 189522000 Open source
20182018-12-31	Liabilities / assets	139.9%	Total Liabilities: 168517000 Open source Total Assets: 120472000 Open source
20192019-12-31	Liabilities / assets	136.5%	Total Liabilities: 180764000 Open source Total Assets: 132440000 Open source
20202020-12-31	Liabilities / assets	49%	Total Liabilities: 168190000 Open source Total Assets: 342940000 Open source
20212021-12-31	Liabilities / assets	62.9%	Total Liabilities: 223352000 Open source Total Assets: 354859000 Open source
20222022-12-31	Liabilities / assets	96.9%	Total Liabilities: 338001000 Open source Total Assets: 348784000 Open source
20232023-12-31	Liabilities / assets	112.5%	Total Liabilities: 403456000 Open source Total Assets: 358600000 Open source
20242024-12-31	Liabilities / assets	90.1%	Total Liabilities: 126026000 Open source Total Assets: 139810000 Open source
20252025-12-31	Liabilities / assets	68%	Total Liabilities: 93975000 Open source Total Assets: 138193000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.56× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	6.51×	Current Assets: 198369000 Open source Current Liabilities: 30457000 Open source
20172017-12-31	Current assets / current liabilities	4.9×	Current Assets: 155078000 Open source Current Liabilities: 31625000 Open source
20182018-12-31	Current assets / current liabilities	2.2×	Current Assets: 92665000 Open source Current Liabilities: 42041000 Open source
20192019-12-31	Current assets / current liabilities	2.18×	Current Assets: 100189000 Open source Current Liabilities: 45993000 Open source
20202020-12-31	Current assets / current liabilities	5.79×	Current Assets: 268777000 Open source Current Liabilities: 46415000 Open source
20212021-12-31	Current assets / current liabilities	3.69×	Current Assets: 303628000 Open source Current Liabilities: 82258000 Open source
20222022-12-31	Current assets / current liabilities	2.28×	Current Assets: 194764000 Open source Current Liabilities: 85596000 Open source
20232023-12-31	Current assets / current liabilities	1.78×	Current Assets: 175410000 Open source Current Liabilities: 98659000 Open source
20242024-12-31	Current assets / current liabilities	0.94×	Current Assets: 38674000 Open source Current Liabilities: 41222000 Open source
20252025-12-31	Current assets / current liabilities	2.56×	Current Assets: 49376000 Open source Current Liabilities: 19322000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 91.58 million Exact value Exact value: -91579000 USD 2016-01-01 – 2016-12-31: -91579000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SERES THERAPEUTICS, INC. · 2016-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Net Income: -91579000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -91579000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000156459019006423/mcrb-20181231.xml#129292 Filing: 000156459019006423 The citation records this snapshot. The page link may show a newer release later.	USD 43.92 million Exact value Exact value: 43921000 USD 2016-01-01 – 2016-12-31: 43921000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SERES THERAPEUTICS, INC. · 2016-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Operating Cash Flow: 43921000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 43921000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000156459019006423/mcrb-20181231.xml#155732 Filing: 000156459019006423 The citation records this snapshot. The page link may show a newer release later.	USD 21.49 million Exact value Exact value: 21492000 USD 2016-01-01 – 2016-12-31: 21492000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SERES THERAPEUTICS, INC. · 2016-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Capital Expenditure: 21492000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 21492000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000156459019006423/mcrb-20181231.xml#156363 Filing: 000156459019006423 The citation records this snapshot. The page link may show a newer release later.	USD 22.43 million Calculation and evidence 43921000 − 21492000 USD Exact free cash flow: 22429000 USD 2016-01-01 – 2016-12-31: 43921000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 21492000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SERES THERAPEUTICS, INC. · 2016-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Free cash flow: 22429000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 43921000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000156459019006423/mcrb-20181231.xml#155732 Filing: 000156459019006423 Input fundies:CapitalExpenditure: 21492000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000156459019006423/mcrb-20181231.xml#156363 Filing: 000156459019006423 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 89.38 million Exact value Exact value: -89380000 USD 2017-01-01 – 2017-12-31: -89380000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SERES THERAPEUTICS, INC. · 2017-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Net Income: -89380000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -89380000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000156459020008002/mcrb-20191231.xml#149322 Filing: 000156459020008002 The citation records this snapshot. The page link may show a newer release later.	−USD 75.52 million Exact value Exact value: -75523000 USD 2017-01-01 – 2017-12-31: -75523000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SERES THERAPEUTICS, INC. · 2017-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Operating Cash Flow: -75523000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -75523000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000156459020008002/mcrb-20191231.xml#178163 Filing: 000156459020008002 The citation records this snapshot. The page link may show a newer release later.	USD 4.68 million Exact value Exact value: 4676000 USD 2017-01-01 – 2017-12-31: 4676000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SERES THERAPEUTICS, INC. · 2017-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Capital Expenditure: 4676000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4676000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000156459020008002/mcrb-20191231.xml#178795 Filing: 000156459020008002 The citation records this snapshot. The page link may show a newer release later.	−USD 80.2 million Calculation and evidence -75523000 − 4676000 USD Exact free cash flow: -80199000 USD 2017-01-01 – 2017-12-31: -75523000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 4676000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SERES THERAPEUTICS, INC. · 2017-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Free cash flow: -80199000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -75523000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000156459020008002/mcrb-20191231.xml#178163 Filing: 000156459020008002 Input fundies:CapitalExpenditure: 4676000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000156459020008002/mcrb-20191231.xml#178795 Filing: 000156459020008002 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 98.94 million Exact value Exact value: -98942000 USD 2018-01-01 – 2018-12-31: -98942000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SERES THERAPEUTICS, INC. · 2018-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Net Income: -98942000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -98942000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000156459021010057/mcrb-10k_20201231.htm#2700295 Filing: 000156459021010057 The citation records this snapshot. The page link may show a newer release later.	−USD 62.85 million Exact value Exact value: -62854000 USD 2018-01-01 – 2018-12-31: -62854000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SERES THERAPEUTICS, INC. · 2018-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Operating Cash Flow: -62854000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -62854000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000156459021010057/mcrb-10k_20201231.htm#2785138 Filing: 000156459021010057 The citation records this snapshot. The page link may show a newer release later.	USD 1.94 million Exact value Exact value: 1937000 USD 2018-01-01 – 2018-12-31: 1937000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SERES THERAPEUTICS, INC. · 2018-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Capital Expenditure: 1937000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1937000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000156459021010057/mcrb-10k_20201231.htm#2796189 Filing: 000156459021010057 The citation records this snapshot. The page link may show a newer release later.	−USD 64.79 million Calculation and evidence -62854000 − 1937000 USD Exact free cash flow: -64791000 USD 2018-01-01 – 2018-12-31: -62854000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 1937000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SERES THERAPEUTICS, INC. · 2018-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Free cash flow: -64791000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -62854000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000156459021010057/mcrb-10k_20201231.htm#2785138 Filing: 000156459021010057 Input fundies:CapitalExpenditure: 1937000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000156459021010057/mcrb-10k_20201231.htm#2796189 Filing: 000156459021010057 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 70.28 million Exact value Exact value: -70279000 USD 2019-01-01 – 2019-12-31: -70279000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SERES THERAPEUTICS, INC. · 2019-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Net Income: -70279000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -70279000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017022002435/mcrb-20211231.htm#2834451 Filing: 000095017022002435 The citation records this snapshot. The page link may show a newer release later.	−USD 76.52 million Exact value Exact value: -76520000 USD 2019-01-01 – 2019-12-31: -76520000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SERES THERAPEUTICS, INC. · 2019-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Operating Cash Flow: -76520000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -76520000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017022002435/mcrb-20211231.htm#2926781 Filing: 000095017022002435 The citation records this snapshot. The page link may show a newer release later.	USD 1 million Exact value Exact value: 1002000 USD 2019-01-01 – 2019-12-31: 1002000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SERES THERAPEUTICS, INC. · 2019-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Capital Expenditure: 1002000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1002000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017022002435/mcrb-20211231.htm#2937042 Filing: 000095017022002435 The citation records this snapshot. The page link may show a newer release later.	−USD 77.52 million Calculation and evidence -76520000 − 1002000 USD Exact free cash flow: -77522000 USD 2019-01-01 – 2019-12-31: -76520000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1002000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SERES THERAPEUTICS, INC. · 2019-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Free cash flow: -77522000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -76520000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017022002435/mcrb-20211231.htm#2926781 Filing: 000095017022002435 Input fundies:CapitalExpenditure: 1002000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017022002435/mcrb-20211231.htm#2937042 Filing: 000095017022002435 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 89.13 million Exact value Exact value: -89127000 USD 2020-01-01 – 2020-12-31: -89127000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SERES THERAPEUTICS, INC. · 2020-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Net Income: -89127000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -89127000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017023006374/mcrb-20221231.htm#3027404 Filing: 000095017023006374 The citation records this snapshot. The page link may show a newer release later.	−USD 93.61 million Exact value Exact value: -93610000 USD 2020-01-01 – 2020-12-31: -93610000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SERES THERAPEUTICS, INC. · 2020-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Operating Cash Flow: -93610000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -93610000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017023006374/mcrb-20221231.htm#3123113 Filing: 000095017023006374 The citation records this snapshot. The page link may show a newer release later.	USD 591,000 Exact value Exact value: 591000 USD 2020-01-01 – 2020-12-31: 591000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SERES THERAPEUTICS, INC. · 2020-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Capital Expenditure: 591000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 591000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017023006374/mcrb-20221231.htm#3134529 Filing: 000095017023006374 The citation records this snapshot. The page link may show a newer release later.	−USD 94.2 million Calculation and evidence -93610000 − 591000 USD Exact free cash flow: -94201000 USD 2020-01-01 – 2020-12-31: -93610000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 591000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SERES THERAPEUTICS, INC. · 2020-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Free cash flow: -94201000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -93610000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017023006374/mcrb-20221231.htm#3123113 Filing: 000095017023006374 Input fundies:CapitalExpenditure: 591000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017023006374/mcrb-20221231.htm#3134529 Filing: 000095017023006374 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 65.58 million Exact value Exact value: -65578000 USD 2021-01-01 – 2021-12-31: -65578000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SERES THERAPEUTICS, INC. · 2021-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Net Income: -65578000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -65578000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017024025464/mcrb-20231231.htm#3227497 Filing: 000095017024025464 The citation records this snapshot. The page link may show a newer release later.	USD 6.69 million Exact value Exact value: 6688000 USD 2021-01-01 – 2021-12-31: 6688000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SERES THERAPEUTICS, INC. · 2021-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Operating Cash Flow: 6688000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 6688000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017024025464/mcrb-20231231.htm#2339149 Filing: 000095017024025464 The citation records this snapshot. The page link may show a newer release later.	USD 9.57 million Exact value Exact value: 9566000 USD 2021-01-01 – 2021-12-31: 9566000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SERES THERAPEUTICS, INC. · 2021-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Capital Expenditure: 9566000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9566000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017024025464/mcrb-20231231.htm#2345996 Filing: 000095017024025464 The citation records this snapshot. The page link may show a newer release later.	−USD 2.88 million Calculation and evidence 6688000 − 9566000 USD Exact free cash flow: -2878000 USD 2021-01-01 – 2021-12-31: 6688000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 9566000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SERES THERAPEUTICS, INC. · 2021-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Free cash flow: -2878000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 6688000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017024025464/mcrb-20231231.htm#2339149 Filing: 000095017024025464 Input fundies:CapitalExpenditure: 9566000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017024025464/mcrb-20231231.htm#2345996 Filing: 000095017024025464 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 250.16 million Exact value Exact value: -250157000 USD 2022-01-01 – 2022-12-31: -250157000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SERES THERAPEUTICS, INC. · 2022-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Net Income: -250157000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -250157000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017025038427/mcrb-20241231.htm#3628643 Filing: 000095017025038427 The citation records this snapshot. The page link may show a newer release later.	−USD 228.82 million Exact value Exact value: -228816000 USD 2022-01-01 – 2022-12-31: -228816000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SERES THERAPEUTICS, INC. · 2022-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Operating Cash Flow: -228816000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -228816000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017025038427/mcrb-20241231.htm#2543410 Filing: 000095017025038427 The citation records this snapshot. The page link may show a newer release later.	USD 9.82 million Exact value Exact value: 9821000 USD 2022-01-01 – 2022-12-31: 9821000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SERES THERAPEUTICS, INC. · 2022-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Capital Expenditure: 9821000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9821000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017025038427/mcrb-20241231.htm#2552214 Filing: 000095017025038427 The citation records this snapshot. The page link may show a newer release later.	−USD 238.64 million Calculation and evidence -228816000 − 9821000 USD Exact free cash flow: -238637000 USD 2022-01-01 – 2022-12-31: -228816000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 9821000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SERES THERAPEUTICS, INC. · 2022-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Free cash flow: -238637000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -228816000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017025038427/mcrb-20241231.htm#2543410 Filing: 000095017025038427 Input fundies:CapitalExpenditure: 9821000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000095017025038427/mcrb-20241231.htm#2552214 Filing: 000095017025038427 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 113.72 million Exact value Exact value: -113724000 USD 2023-01-01 – 2023-12-31: -113724000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SERES THERAPEUTICS, INC. · 2023-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Net Income: -113724000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -113724000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2611076 Filing: 000119312526103276 The citation records this snapshot. The page link may show a newer release later.	−USD 117.35 million Exact value Exact value: -117354000 USD 2023-01-01 – 2023-12-31: -117354000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SERES THERAPEUTICS, INC. · 2023-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Operating Cash Flow: -117354000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -117354000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2748325 Filing: 000119312526103276 The citation records this snapshot. The page link may show a newer release later.	USD 7.98 million Exact value Exact value: 7975000 USD 2023-01-01 – 2023-12-31: 7975000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SERES THERAPEUTICS, INC. · 2023-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Capital Expenditure: 7975000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7975000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2757771 Filing: 000119312526103276 The citation records this snapshot. The page link may show a newer release later.	−USD 125.33 million Calculation and evidence -117354000 − 7975000 USD Exact free cash flow: -125329000 USD 2023-01-01 – 2023-12-31: -117354000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 7975000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SERES THERAPEUTICS, INC. · 2023-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Free cash flow: -125329000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -117354000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2748325 Filing: 000119312526103276 Input fundies:CapitalExpenditure: 7975000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2757771 Filing: 000119312526103276 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	USD 136,000 Exact value Exact value: 136000 USD 2024-01-01 – 2024-12-31: 136000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SERES THERAPEUTICS, INC. · 2024-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Net Income: 136000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: 136000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2609331 Filing: 000119312526103276 The citation records this snapshot. The page link may show a newer release later.	−USD 148.61 million Exact value Exact value: -148609000 USD 2024-01-01 – 2024-12-31: -148609000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SERES THERAPEUTICS, INC. · 2024-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Operating Cash Flow: -148609000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -148609000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2746434 Filing: 000119312526103276 The citation records this snapshot. The page link may show a newer release later.	USD 380,000 Exact value Exact value: 380000 USD 2024-01-01 – 2024-12-31: 380000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SERES THERAPEUTICS, INC. · 2024-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Capital Expenditure: 380000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 380000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2755997 Filing: 000119312526103276 The citation records this snapshot. The page link may show a newer release later.	−USD 148.99 million Calculation and evidence -148609000 − 380000 USD Exact free cash flow: -148989000 USD 2024-01-01 – 2024-12-31: -148609000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 380000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SERES THERAPEUTICS, INC. · 2024-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Free cash flow: -148989000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -148609000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2746434 Filing: 000119312526103276 Input fundies:CapitalExpenditure: 380000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2755997 Filing: 000119312526103276 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	USD 5.7 million Exact value Exact value: 5696000 USD 2025-01-01 – 2025-12-31: 5696000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SERES THERAPEUTICS, INC. · 2025-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Net Income: 5696000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: 5696000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2607698 Filing: 000119312526103276 The citation records this snapshot. The page link may show a newer release later.	USD 1.12 million Exact value Exact value: 1117000 USD 2025-01-01 – 2025-12-31: 1117000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SERES THERAPEUTICS, INC. · 2025-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Operating Cash Flow: 1117000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 1117000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2744563 Filing: 000119312526103276 The citation records this snapshot. The page link may show a newer release later.	USD 252,000 Exact value Exact value: 252000 USD 2025-01-01 – 2025-12-31: 252000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SERES THERAPEUTICS, INC. · 2025-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Capital Expenditure: 252000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 252000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2754223 Filing: 000119312526103276 The citation records this snapshot. The page link may show a newer release later.	USD 865,000 Calculation and evidence 1117000 − 252000 USD Exact free cash flow: 865000 USD 2025-01-01 – 2025-12-31: 1117000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 252000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SERES THERAPEUTICS, INC. · 2025-12-31 SERES THERAPEUTICS, INC. (edgar:1609809) Free cash flow: 865000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:46:43Z Snapshot: 1a09d6d4f969d05d77847220e23ab1e8b2dc897a74afaf8be490f19130dcd479 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609809?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 1117000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2744563 Filing: 000119312526103276 Input fundies:CapitalExpenditure: 252000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#2754223 Filing: 000119312526103276 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

61 filings · 2,948 latest values · 2,952 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001609809, 1609809, MCRB, edgar:1609809

Also known as SERES THERAPEUTICS, INC., Seres Health, Inc., Seres Therapeutics, Inc.

SERES THERAPEUTICS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation